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beamlets that would deliver dose to the target after passing a 
prosthesis (IMRTremove, recommended by AAPM), and ii) exclusion of 
only those beamlets including a 5 mm margin (IMRTcut). Plans with 
optimized coplanar and non-coplanar beam arrangements were 
generated. Differences in PTV coverage and sparing of organs at risk 
(OARs) were quantified. The impact of beam number on plan quality 
was evaluated. 
Results: Especially for patients with bilateral hip prostheses, IMRTcut 
significantly improved rectum and bladder sparing compared to 
IMRTremove. For 9-beam coplanar plans, rectum V60Gy reduced by 17.5% 
± 15.0% (maximum 37.4%, p = 0.036) and rectum Dmean by 9.4% ± 7.8% 
(maximum 19.8%, p = 0.036). PTV coverage was similar, except for 
one patient who had a V95% of only 22.3% for IMRTremove, compared to 
99.1% for IMRTcut. Improved PTV coverage was only possible with a 
higher dose in all OARs (see figure). Further improvements in OAR 
sparing were achieved by using non-coplanar beam set-ups, reducing 
rectum V60Gy by another 4.6% ± 4.9% (p = 0.012) for non-coplanar 9-
beam IMRTcut plans. Large reductions in rectum dose delivery were 
also observed when increasing the number of optimized beam 
directions in the plans. For bilateral implants, rectum V60Gy was 37.3% 
± 12.1% for coplanar 7-beam IMRTcut plans which reduced on average 
by 13.5% (maximum 30.1%, p = 0.012) for 15 optimized beam 
directions. 
Conclusions: For prostate cancer patients with metal hip implants, 
iCycle was able to automatically generate high quality, patient-
specific IMRT plans with optimized coplanar or non-coplanar beam 
arrangements. Excluding only beamlets that would deliver dose to the 
PTV after passing through a prosthesis significantly improved OAR 
sparing for patients with bilateral implants as opposed to the AAPM 
taskgroup 63 recommendation. Non-coplanar beam arrangements and, 
to a larger extent, increasing the number of optimized treatment 
beams further improved plan quality. 
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Purpose/Objective: Stereotactic body radiotherapy (SBRT) for non-
small-cell lung cancer (NSCLC) has led to promising local control and 
overall survival for fractionation schemes with increasingly high 
fractional doses. A point has however been reached where too few 
fractions may be used to allow efficient inter-fraction reoxygenation 
(IFR) of the hypoxic cells possibly residing in the tumours. It was the 
purpose of this study to investigate the impact of hypoxia and 
extreme hypofractionation on the tumour control probability (TCP) 
using realistic 3D-models of tumour oxygenation. 
Materials and Methods: 3D-models of tumour oxygenation have been 
based on previous calculations of tumour oxygenation at cellular level 
for various distributions of intervascular distances. The models took 
into account dynamic changes in the oxygenation of the tumours 
between fractions. Simulations were performed for currently used 
fractionation schemes for NSCLC and for theoretical dose prescriptions 
that may be used in SBRT. Clinically relevant dose distributions were 
used to ensure the fulfilment of prescription details for dose 
escalation, dose to the PTV periphery and maximum dose. Cellular 
response was assessed with the LQ model at voxel level and a Poisson 
TCP model at tumour level. 
Results: Calculated tumour control probabilities with IFR agree best 
with reported clinical local control for multi-fraction schemes (Table 
1). The largest disagreement between the clinical figures and the 
calculated values are seen for the single-fraction schemes which could 
be caused by other biophysical processes believed to take place at 
high doses, but not included in the model, such as vascular 
endothelial apoptosis.TCP curves for 1, 3 and 5 fractions with and 
without IFR (Figure 1) demonstrate the importance of allowing for IFR. 
Furthermore, they suggest that 3 or 5 fractions are enough to ensure 
IFR. 
 
Table 1. Examples of calculated TCP with and without IFR for the 
dose schemes pertinent to current clinical practice in the SBRT 
treatment of NSCLC with clinical figures of survival and local control. 
Normal- and tumour tissue BED:s are also given.  
 
† Dose range 24-40 Gy, 69% was given 37.5Gy  
‡ Based on 60 Gy totaldoses given in 3, 5 and 8 fractions: 3x20 
Gy(33%), 5x12 Gy (50%), 8x7.5 Gy(17%) 
 
 
 
Conclusions: Single-fraction stereotactic treatments may require a 
considerable increase in dose per fraction, well above fractional doses 
used today, to counteract the radioresistance of hypoxic cells. 
Although attractive from an economical and practical viewpoint, 
extreme hypofractionation in SBRT should therefore be pursued with 
caution as the reduced possibility for IFR may result in impaired local 
control.  
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Purpose/Objective: One of the worst radiation induced acute effects 
in treating head-and-neck (HN) cancer is grade 3 or higher acute (oral 
and pharyngeal) mucosal toxicity(AMT), caused by the killing/ 
depletion of mucosa cells. Late toxicity are reported after altered 
radiotherapy schedules. The paper aims attesting a predictive model 
of the AMT, as well as late toxicity, in HN cancer patients receiving 
different radiotherapy schedules. 
Materials and Methods: Various radio-therapeutic schedules have 
been reviewed and classified as tolerable or intolerable based on AMT 
 
Dose 
prescr. 
BED3 
(Gy3) 
BED10 
(Gy10) 
Treatment outcome TCP (%) 
Overall 
suvival 
Local 
control 
No 
reox IFR 
3x12.5 
Gy, 
60% 
isodose 
193.8 84.4 
80% at 1 
year† 
75% at 2 
years† 
100% at 1 
year† 
87% at 2 
years† 
10 99 
5x10 Gy,
80% 
isodose 
216.7 100.0 
90/63% at 3 
years 
(Stage 
1A/1B) 
93/96% at 3 
years 
(Stage 
1A/1B) 
0 99 
8x7.5 Gy,
80% 
isodose 
210.0 105.0 
85.7% at 1 
year‡ 
54% at 2 
years‡ 
45.1% at 3 
years‡ 
89% at 3 
years‡ 0 100
